PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
0.00 - 0.01
0.00 - 0.02
1.30M / 496.9K (Avg.)
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
100.00%
Revenue growth of 100.00% while XRF.AX is flat. Bruce Berkowitz would check if a small edge can widen further.
10.33%
Gross profit growth of 10.33% while XRF.AX is zero. Bruce Berkowitz would see if minimal improvements could expand further.
78.01%
EBIT growth of 78.01% while XRF.AX is zero. Bruce Berkowitz would see if small gains can be scaled further.
78.01%
Operating income growth of 78.01% while XRF.AX is zero. Bruce Berkowitz would see if this modest edge can become significant.
100.00%
Net income growth of 100.00% while XRF.AX is zero. Bruce Berkowitz would see if small gains can accelerate into a larger gap.
100.00%
EPS growth of 100.00% while XRF.AX is zero. Bruce Berkowitz would see if minimal gains can accelerate over time.
90.00%
Diluted EPS growth of 90.00% while XRF.AX is zero. Bruce Berkowitz would see if minimal gains can be scaled further for a bigger lead.
0.88%
Share change of 0.88% while XRF.AX is at zero. Bruce Berkowitz would see if slight buybacks (or dilution) matter in the bigger picture.
1.61%
Diluted share change of 1.61% while XRF.AX is zero. Bruce Berkowitz might see a minor difference that could widen over time.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Negative OCF growth while XRF.AX is at 0.00%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-100.08%
Negative FCF growth while XRF.AX is at 0.00%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
26555.94%
10Y revenue/share CAGR above 1.5x XRF.AX's 193.42%. David Dodd would confirm if management’s strategic vision consistently outperforms the competitor.
1181.48%
5Y revenue/share CAGR above 1.5x XRF.AX's 125.34%. David Dodd would look for consistent product or market expansions fueling outperformance.
273.22%
3Y revenue/share CAGR above 1.5x XRF.AX's 105.71%. David Dodd would confirm if there's an emerging competitive moat driving recent gains.
-4108.13%
Negative 10Y OCF/share CAGR while XRF.AX stands at 155.12%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
-13639.91%
Negative 5Y OCF/share CAGR while XRF.AX is at 1715.67%. Joel Greenblatt would question the firm’s operational model or cost structure.
-243.07%
Negative 3Y OCF/share CAGR while XRF.AX stands at 54.98%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
1403.26%
Net income/share CAGR above 1.5x XRF.AX's 144.08% over 10 years. David Dodd would confirm if brand, IP, or scale secure this persistent advantage.
3061.96%
5Y net income/share CAGR above 1.5x XRF.AX's 673.69%. David Dodd would confirm if the firm’s strategy is more effective in generating mid-term profits.
440.05%
3Y net income/share CAGR above 1.5x XRF.AX's 157.74%. David Dodd would confirm the company’s short-term strategies outmatch the competitor significantly.
60878.89%
10Y equity/share CAGR above 1.5x XRF.AX's 63.41%. David Dodd would confirm if consistent earnings retention or fewer write-downs drive this advantage.
235.90%
5Y equity/share CAGR above 1.5x XRF.AX's 51.62%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.
64.91%
3Y equity/share CAGR above 1.5x XRF.AX's 34.97%. David Dodd verifies the company’s short-term capital management far exceeds the competitor’s pace.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
32.21%
AR growth of 32.21% while XRF.AX is zero. Bruce Berkowitz wonders if the firm’s additional AR is warranted by strong revenue or potential risk.
No Data
No Data available this quarter, please select a different quarter.
3.65%
Asset growth of 3.65% while XRF.AX is zero. Bruce Berkowitz checks if modest expansions can create a longer-term lead.
-0.87%
We have a declining book value while XRF.AX shows 0.00%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
3.31%
Debt growth of 3.31% while XRF.AX is zero. Bruce Berkowitz sees additional leverage that must yield profitable expansions to be worthwhile.
No Data
No Data available this quarter, please select a different quarter.
-4.59%
We cut SG&A while XRF.AX invests at 0.00%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.